AU2020267356B2 - KCNT1 inhibitors and methods of use - Google Patents

KCNT1 inhibitors and methods of use Download PDF

Info

Publication number
AU2020267356B2
AU2020267356B2 AU2020267356A AU2020267356A AU2020267356B2 AU 2020267356 B2 AU2020267356 B2 AU 2020267356B2 AU 2020267356 A AU2020267356 A AU 2020267356A AU 2020267356 A AU2020267356 A AU 2020267356A AU 2020267356 B2 AU2020267356 B2 AU 2020267356B2
Authority
AU
Australia
Prior art keywords
6alkyl
group
phenyl
6alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020267356A
Other languages
English (en)
Other versions
AU2020267356A1 (en
Inventor
Paul S. Charifson
Andrew Mark Griffin
Michael Kristopher Mathieu KAHLIG
Brian Edward Marron
Gabriel Martinez Botella
Kiran Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Publication of AU2020267356A1 publication Critical patent/AU2020267356A1/en
Application granted granted Critical
Publication of AU2020267356B2 publication Critical patent/AU2020267356B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020267356A 2019-05-03 2020-05-01 KCNT1 inhibitors and methods of use Active AU2020267356B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US62/842,849 2019-05-03
US202062982864P 2020-02-28 2020-02-28
US62/982,864 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Publications (2)

Publication Number Publication Date
AU2020267356A1 AU2020267356A1 (en) 2022-01-06
AU2020267356B2 true AU2020267356B2 (en) 2025-04-24

Family

ID=73051241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020267356A Active AU2020267356B2 (en) 2019-05-03 2020-05-01 KCNT1 inhibitors and methods of use

Country Status (17)

Country Link
US (1) US20220259193A1 (enExample)
EP (1) EP3962481A4 (enExample)
JP (2) JP7667573B2 (enExample)
KR (1) KR20220016086A (enExample)
CN (2) CN120817941A (enExample)
AU (1) AU2020267356B2 (enExample)
BR (1) BR112021022067A2 (enExample)
CA (1) CA3139063A1 (enExample)
CL (2) CL2021002877A1 (enExample)
CO (1) CO2021016471A2 (enExample)
EC (1) ECSP21087884A (enExample)
IL (1) IL287768A (enExample)
MX (1) MX2021013421A (enExample)
PE (1) PE20220016A1 (enExample)
SA (1) SA521430751B1 (enExample)
SG (1) SG11202112158YA (enExample)
WO (1) WO2020227101A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
WO2020227097A1 (en) * 2019-05-03 2020-11-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
CA3169779A1 (en) * 2020-02-28 2021-09-02 Andrew Mark Griffin Kcnt1 inhibitors and methods of use
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
CN116194451B (zh) * 2020-11-27 2025-07-11 瑞石生物医药有限公司 芳基或杂芳基取代五元芳杂环化合物及其用途
EP4267133A4 (en) * 2020-12-22 2025-01-22 Praxis Precision Medicines, Inc. KCNT1 INHIBITORS AND METHODS OF USE
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US20240368142A1 (en) * 2021-04-29 2024-11-07 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2023239839A1 (en) * 2022-06-08 2023-12-14 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
WO2025117662A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors
US20260109692A1 (en) 2024-10-18 2026-04-23 UCB Biopharma SRL Kcnt1 inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
CA2962922C (en) 2014-09-29 2021-10-26 The Scripps Research Institute Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
US10538516B2 (en) * 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
CA3169779A1 (en) * 2020-02-28 2021-09-02 Andrew Mark Griffin Kcnt1 inhibitors and methods of use
AU2021241530A1 (en) * 2020-03-23 2022-10-20 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
KR20230035608A (ko) * 2020-07-06 2023-03-14 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
EP4267133A4 (en) * 2020-12-22 2025-01-22 Praxis Precision Medicines, Inc. KCNT1 INHIBITORS AND METHODS OF USE
US20240368142A1 (en) * 2021-04-29 2024-11-07 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤

Also Published As

Publication number Publication date
CL2021002877A1 (es) 2022-08-12
US20220259193A1 (en) 2022-08-18
WO2020227101A1 (en) 2020-11-12
JP2025102975A (ja) 2025-07-08
CL2024002067A1 (es) 2024-12-13
BR112021022067A2 (pt) 2022-05-17
KR20220016086A (ko) 2022-02-08
CN120817941A (zh) 2025-10-21
ECSP21087884A (es) 2022-01-31
PE20220016A1 (es) 2022-01-11
SA521430751B1 (ar) 2024-02-01
MX2021013421A (es) 2022-02-11
IL287768A (en) 2022-01-01
JP2022531388A (ja) 2022-07-06
CN114269340A (zh) 2022-04-01
JP7667573B2 (ja) 2025-04-23
SG11202112158YA (en) 2021-12-30
CO2021016471A2 (es) 2022-04-08
AU2020267356A1 (en) 2022-01-06
EP3962481A1 (en) 2022-03-09
CA3139063A1 (en) 2020-11-12
EP3962481A4 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
AU2020267356B2 (en) KCNT1 inhibitors and methods of use
TWI490202B (zh) 昇糖素受體調節劑
CN108774214B (zh) 作为激酶抑制剂的杂环酰胺
EP3939974A1 (en) Modulators of ror-gamma
EP3704118B1 (en) Aminoimidazopyridazines as kinase inhibitors
WO2014074675A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
TW202342458A (zh) Ｐａｒｇ抑制劑
WO2018148626A1 (en) Aminotriazolopyridines as kinase inhibitors
JP7824664B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
BR112013026905B1 (pt) Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos
EP4110317B1 (en) Kcnt1 inhibitors and methods of use
US20240043415A1 (en) Kcnt1 inhibitors and methods of use
AU2021227935B2 (en) KCNT1 inhibitors and methods of use
WO2017076349A1 (zh) 长效二肽基肽酶-iv抑制剂、其用途及其制备方法
HK40069627A (en) Modulators of ror-gamma
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ
NZ616395B2 (en) Androgen receptor modulating carboxamides for the treatment of cancer
HK40001214B (en) Benzimidazole derivatives as modulators of ror-gamma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)